abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Acute Myeloid Leukemia · Narcolepsy · JAZZ
Jazz Pharmaceuticals Ireland
Jazz Pharmaceuticals Ireland Limited
Jazz Pharmaceuticals Ireland drug portfolio — 72 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waterloo Exchange, Waterloo Road, Dublin, 4, IE HQ
2003 Founded
3,631 Employees
Public company Type
JAZZ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waterloo Exchange, Waterloo Road, Dublin, 4, IE
- Founded
- 2003
- Employees
- 3,631
- Programs
- 10
- Drugs
- 72
- Patents
- 36
Jazz Pharmaceuticals Ireland pipeline
Portfolio lens on 72 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jazz Pharmaceuticals Ireland drug portfolio — 72 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
asparaginase
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio.
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase.
- Target
- DNA polymerase
- Mechanism
- DNA polymerase inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cidofovir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Jazz Pharmaceuticals Ireland's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
crisantaspase
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
defibrotide
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Adenosine receptor A1.
- Target
- Adenosine receptor A1
- Mechanism
- Adenosine A1 receptor agonist
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Plasminogen activator
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor agonist
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP], mitochondrial.
- Target
- Isocitrate dehydrogenase [NADP], mitochondrial
- Mechanism
- Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved. Molecular target: Thymidylate synthase.
- Target
- Thymidylate synthase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
gemtuzumab ozogamicin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Myeloid cell surface antigen CD33 binding agent
-
gilteritinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Receptor-type tyrosine-protein kinase FLT3.
- Target
- Receptor-type tyrosine-protein kinase FLT3
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
US regulatory status: approved. Molecular target: Receptor-type tyrosine-protein kinase FLT3.
- Target
- Receptor-type tyrosine-protein kinase FLT3
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
glasdegib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Protein smoothened.
- Target
- Protein smoothened
- Mechanism
- Smoothened homolog antagonist
-
US regulatory status: approved. Molecular target: Protein smoothened.
- Target
- Protein smoothened
- Mechanism
- Smoothened homolog antagonist
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
lurbinectedin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA negative modulator
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
palbociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CDK6/cyclin D1.
- Target
- CDK6/cyclin D1
- Mechanism
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pertuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Molecular target: Bacterial DNA-directed RNA polymerase.
- Target
- Bacterial DNA-directed RNA polymerase
- Mechanism
- Bacterial DNA-directed RNA polymerase inhibitor
-
sodium oxybate
Nervous system (N07)US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
solriamfetol
Nervous system (N06)US regulatory status: approved.
-
tislelizumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
trastuzumab emtansine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Jazz Pharmaceuticals Ireland in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
zanidatamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Jazz Pharmaceuticals Ireland's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor